

7/21/2022

Conflict of Interest Disclosures Blood Advances

00000427017	Catherine M. Bollard, MD	Editor Designee	Last Confirmed Date: 08/05/2020
--------------------	---------------------------------	------------------------	--

Company:	Relationship:	Additional Information	End Date
Caballeta Bio	Equity Ownership	Stock options	01/01/2040
Caballeta Bio	Membership on a Board or Advisory Committee	Member of the Board of Directors with stock options	01/01/2040
Catamaran Bio	Membership on a Board or Advisory Committee	SAB member	
Collectis	Honoraria		01/01/2040
Collectis	Membership on a Board or Advisory Committee		01/01/2040
Mana Therapeutics	Equity Ownership		01/01/2039
Mana Therapeutics	Membership on a Board or Advisory Committee	Serve on Scientific Advisory Board	01/01/2039
Mana Therapeutics	Patents & Royalties		01/01/2039
Neximmune	Equity Ownership	Own stock	01/01/2040
Repertoire	Equity Ownership	Stock	12/01/2024

00000427571	Michael R. DeBaun	Associate Editor	Last Confirmed Date: 08/07/2018
--------------------	--------------------------	-------------------------	--

Company:	Relationship:	Additional Information	End Date
	Nothing to disclose.		

00001011105	Saar Gill, MD,PhD	Associate Editor	Last Confirmed Date: 01/16/2021
--------------------	--------------------------	-------------------------	--

Company:	Relationship:	Additional Information	End Date
Carisma Therapeutics	Equity Ownership	Equity ownership	01/01/2024
Carisma Therapeutics	Patents & Royalties	patents	01/01/2024
Carisma Therapeutics	Research Funding		01/01/2021
Intellia	Membership on a Board or Advisory Committee	SAB	01/01/2021
Interius Biotherapeutics	Research Funding		01/01/2040
Tmunity	Research Funding	research funding	12/31/2020

Conflict of Interest Disclosures Blood Advances

00000429652	Geoff Hill, MD	Associate Editor	Last Confirmed Date: 02/04/2019
Company:	Relationship:	Additional Information	End Date
Implicit Biosciences	Research Funding	Research funding for preclinical studies of CD14 mAb in GVHD	01/01/2020
Pharmacyclics	Research Funding	Research funding support for immune analysis of phase 3 study of Ibrutinib in chronic GVHD	07/01/2020
QIMR Berghofer Medical Research Institute	Patents & Royalties	Provisional patent lodged for prevention and treatment of CMV with strain-specific Ab	
QIMR Berghofer Medical Research Institute	Patents & Royalties	Provisional patents lodged for methods to (i) prevent inflammation and (ii) prevent and treat CMV reactivation	01/01/2021

Conflict of Interest Disclosures Blood Advances

00000430052	Leslie Kean, MD, PhD	Associate Editor	Last Confirmed Date: 09/11/2020
--------------------	-----------------------------	-------------------------	--

Company:	Relationship:	Additional Information	End Date
	Consultancy		01/01/2040
	Consultancy	NHP research consultant	01/01/2040
	Research Funding		01/01/2040
	Speakers Bureau		01/01/2040
Bluebird Bio	Research Funding	NHP research funding.	
Bristol Myers Squibb	Research Funding		01/01/2040
EMD Serono	Consultancy	NHP research	
Equilium	Consultancy		
FortySeven	Consultancy		
Gilead	Consultancy	immune tolerance	
HiFi Bio	Membership on a Board or Advisory Committee	SAB member	
Interrius	Consultancy	NHP research	
Kymab	Consultancy		
Magenta	Consultancy		01/01/2020
Magenta	Research Funding	NHP transplant research	01/01/2040
Novartis	Research Funding	NHP research	
Regeneron	Research Funding	NHP research	
Sana	Consultancy	NHP research	

00001006795	Claudia Lengerke	Associate Editor	Last Confirmed Date: 02/01/2021
--------------------	-------------------------	-------------------------	--

Company:	Relationship:	Additional Information	End Date
	Employment	employment as physician-scientist in the Hematology/Oncology Department	01/01/2038
	Research Funding	Max Eder Junior Group Leader Program	
Daiichi Sankyo	Speakers Bureau	Talk at AML satellite workshop of the German, Austrian and Swiss Societies of Hematology/Oncology Annual Meeting	10/09/2019

Conflict of Interest Disclosures Blood Advances

000001267024	Ryan Morin, PhD	Associate Editor	Last Confirmed Date: 02/11/2021
Company:	Relationship:	Additional Information	End Date
	Nothing to disclose.		09/15/2020
Celgene	Consultancy	I provide data analysis and general guidance on ongoing genome sequencing project from clinical trials and internal research projects run by Celgene.	
Epizyme	Patents & Royalties	I am an inventor on a patent relating to EZH2 mutations that is currently licensed by Epizyme.	
Foundation for Burkitt Lymphoma Research	Membership on a Board or Advisory Committee	I am on the scientific advisory board for this charitable foundation.	

Conflict of Interest Disclosures Blood Advances

00000424143	Nikhil C. Munshi, MD	Associate Editor	Last Confirmed Date: 07/25/2019
Company:	Relationship:	Additional Information	End Date
Abbvie	Consultancy		
Amgen	Consultancy		01/01/2020
Celgene	Consultancy		01/01/2020
Celgene	Consultancy		
Celgene	Honoraria		
Celgene	Membership on a Board or Advisory Committee		01/01/2038
Celgene	Speakers Bureau		
Janssen	Consultancy		01/01/2020
Janssen Pharmaceutical	Consultancy		
Millennium	Honoraria		
Millennium	Speakers Bureau		
Novartis	Honoraria		
Novartis	Speakers Bureau		
Oncoprep	Consultancy		01/01/2020
Oncoprep	Consultancy		
Oncoprep	Equity Ownership		01/01/2036
Oncoprep	Equity Ownership		
Oncoprep	Membership on a Board or Advisory Committee		01/01/2020
Oncoprep	Membership on a Board or Advisory Committee		
Oncoprep	Patents & Royalties		01/01/2020
Onyx	Membership on a Board or Advisory Committee		
Takeda	Consultancy		01/01/2020

Conflict of Interest Disclosures Blood Advances

000000124518	Robert Negrin, MD	Editor	Last Confirmed Date: 01/13/2021
Company:	Relationship:	Additional Information	End Date
	Equity Ownership		01/01/2035
Amgen	Consultancy		01/01/2020
Applied Stem Cell	Consultancy		
BioEclipse Therapeutics	Equity Ownership		01/01/2038
BioEclipse Therapeutics	Membership on a Board or Advisory Committee		01/01/2038
Cell Source	Consultancy		01/01/2036
Cell Source	Equity Ownership		01/01/2036
Formula	Equity Ownership		
Formula	Membership on a Board or Advisory Committee		
Jazz	Consultancy		
Kuur Therapeutics	Membership on a Board or Advisory Committee		
Magenta	Equity Ownership		
Magenta	Membership on a Board or Advisory Committee		
Regimmune	Consultancy		
University of Pennsylvania	Membership on a Board or Advisory Committee	DSMB for a clinical study of CAR T cells	
UpToDate	Consultancy		01/01/2035

Conflict of Interest Disclosures Blood Advances

000000122821	Margaret V. Ragni, MD,MPH	Associate Editor	Last Confirmed Date: 02/11/2021
Company:	Relationship:	Additional Information	End Date
	Honoraria		01/01/2035
	Honoraria		01/01/2036
	Honoraria		01/01/2038
	Membership on a Board or Advisory Committee		01/01/2035
	Membership on a Board or Advisory Committee		01/01/2038
	Membership on a Board or Advisory Committee	The Hematologist (ASH) Editorial Board 2011-	01/01/2038
	Research Funding		01/01/2020
	Research Funding		01/01/2022
	Research Funding		01/01/2034
	Research Funding		01/01/2035
	Research Funding		01/01/2038
Alnylam	Membership on a Board or Advisory Committee		01/01/2026
Alnylam	Research Funding	This is for participation in phase 1, 2, 3 studies of novel bypass, siRNA-AT3, fitusiran.	01/01/2026
Baxter Bioscience	Honoraria		
Baxter Bioscience	Research Funding	1. Research studies involving recombinant VWF in Von Willebrand disease. This provides funds to study dendritic cells in inducing tolerance in hemophilia A mice with inhibitors. 2. Dendritic cell vaccine in tolerance induction in hemophilia A mouse, Co-PI 3. Recombinant VWF PK and Safety study, Co-investigator 4. FVIIa BI Dose Escalation Study, Co-investigator	01/01/2020

Conflict of Interest Disclosures Blood Advances

Bayer	Consultancy		
Bayer	Research Funding		
Biogen Idec	Consultancy		
Biogen Idec	Research Funding		
BioMarin	Membership on a Board or Advisory Committee		
BioMarin	Research Funding	This is a research trial of BMN gene therapy for hemophilia A.	01/01/2025
Bioverativ/Sanofi	Membership on a Board or Advisory Committee		
Bioverativ/Sanofi	Research Funding	Investigator-Initiated Research: To use FVIII Fc for ITI (HIRE trial)	01/01/2026
		Research study of long-acting FVIII Fc-VWF-XTEN	
Bristol Myers Squibb	Research Funding		
CSL Behring	Research Funding	1.Subcontract (UNC) Deep venous thrombosis in Hemophilia, Co-investigator	01/01/2023
		2.FVIIa-FP Phase III Trial in Hemophilia Inhibitor Patients, Co-Investigator	
Foundation for Women and Girls with Blood Disorders	Membership on a Board or Advisory Committee	Foundation for Women and Girls with Blood Disorders, Medical Advisory Board (2010-)	01/01/2050
Institute for Cost Effectiveness Research (ICER)	Consultancy	Participation in review and public discussion of a white paper on cost-effectiveness of novel bypass Hemlibra (emicizumab) in hemophilia inhibitor patients.	01/01/2050
NovoNordisk	Research Funding	n/a	01/01/2020
OPKO Biologics	Research Funding	Clinical Trial funding: Phase 1/2 Study to Assess Safety and Pharmacokinetics of Long Acting VIIa in Hemophilia A and B.	01/01/2020
Pfizer	Research Funding	FVIIa Variant in Hemophilia Inhibitor Patients	01/01/2020

Conflict of Interest Disclosures Blood Advances

SPARK	Membership on a Board or Advisory Committee		
SPARK	Research Funding	n/a	01/01/2025
Tacere Benitec	Research Funding		
Takeda Pharmaceuticals	Research Funding	NA	01/01/2024

00000125050	Wendy Stock	Associate Editor	Last Confirmed Date: 02/01/2021
--------------------	--------------------	-------------------------	--

Company:	Relationship:	Additional Information	End Date
Abbvie	Speakers Bureau		
Agios	Consultancy		
Amgen	Consultancy		
astellas	Membership on a Board or Advisory Committee		
Glaxo Smith Kline	Consultancy		
Kite/Gilead	Consultancy		
Kura	Consultancy		
MorphoSys	Consultancy		
Servier	Consultancy		
Up to Date	Patents & Royalties		

00001004255	Constantine S. Tam, MBBS	Associate Editor	Last Confirmed Date: 01/17/2021
--------------------	---------------------------------	-------------------------	--

Company:	Relationship:	Additional Information	End Date
AbbVie	Honoraria		
AbbVie	Research Funding		
Beigene	Honoraria		
Celgene	Honoraria		
Janssen	Honoraria		01/01/2038
Janssen	Research Funding		
Novartis	Honoraria		
Pharmacyclics	Honoraria		
Roche	Honoraria		

Conflict of Interest Disclosures Blood Advances

00001009344	Andrew S. Weyrich, PhD	Associate Editor	Last Confirmed Date: 01/21/2021
--------------------	-------------------------------	-------------------------	--

Company:	Relationship:	Additional Information	End Date
	Nothing to disclose.		